A Phase 2 interventional study of LY686017 and Placebo in Alcohol Dependence, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.
Among the 1,073 studies in Alcoholism with a site in United States, this one is the 210th largest by enrollment of the 989 interventional ones that give a count, is one of 39 that started in 2008, is one of 247 in phase 2, and was the 238th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 21–65
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 21–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,073 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 138 · Phase 2 312 · Phase 3 77 · Phase 4 96
First in 1992; this study’s year is marked. 39 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 80 across the 989 interventional studies, 109 across the 79 observational. Of the 779 that completed or were terminated, 371 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 1,073 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 7 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
82 of the studies in Alcoholism with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06173973Phase 3University of PennsylvaniaEffects of Ketone Supplementation on Acute Alcohol Withdrawal | 2026-12 |
| NCT05015881Phase 3University of PennsylvaniaRelationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder | 2026-12 |
| NCT04616781Phase 3University of PennsylvaniaKetone Ester Intervention in Alcohol Use Disorder | 2026-12 |
| NCT06702007Phase 3University of WashingtonElectronic Harm Reduction Treatment for Alcohol | 2027-01 |
| NCT05613608Phase 3University of Colorado, DenverAlcohol Use Disorder and Cannabidiol | 2027-04 |
Add all 82 to your calendar (.ics) → With an account.
Among the 1,073 studies in Alcoholism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: LY686017
50 milligrams (mg) daily by oral route for 12 weeks
Daily by oral route for 12 weeks
Percent Change From Baseline in Heavy Drinking Days
The Alcohol Timeline Followback (TLFB) is used in calculating the percent reduction in heavy drinking days. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day during last 4 weeks. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men.
Time frame: Baseline, Weeks 4 and 8 and 12 and 16
Percent Days Abstinent Per Month
The Alcohol Timeline Followback (TLFB) is used in calculating the percentage of days abstinent (days where no alcoholic drinks were consumed). The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Percentage days per month= (number of days where no alcoholic beverages were consumed/number of days in a month)\*100.
Time frame: Baseline and Weeks 4 and 8 and 12 and 16.
Number of Drinks Per Drinking Day During a Month
The Alcohol Timeline Followback (TLFB) is used in calculating the number of drinks per drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv).
Time frame: Baseline and Weeks 4 and 8 and12 and 16
Time to First Heavy Drinking Day
The Alcohol Timeline Followback (TLFB) is used to assess the time to first heavy drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. Those who did not drink are considered to be "censored."
Time frame: Baseline up to Week 12
Change From Baseline in Drinker Inventory of Consequences (DrInC) Subscale and Total Scale
DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. All items for the DrInC are scored from 0-3 with higher scores indicating worse adverse consequences. Interpersonal subscale (10 items: scores range from 0-30) measures the impact of drinking on the participants' relationships. Physical subscale (8 items: scores range from 0-24) measures adverse physical states resulting from excessive drinking. Social subscale (7 items: scores range from 0-21) measures role fulfillment. Impulsive subscale (12 items: scores range from 0-36) measures sequelae of over drinking. Intrapersonal subscale (8 items: scores range from 0-24) measures subjective perceptions that may not be readily observable by others. Total scores range from 0-150, with higher scores indicating greater severity of symptoms.
Time frame: Baseline, Week 12
Change From Baseline in Alcohol Urge Questionnaire (AUQ)
AUQ measures participant's feeling and thoughts about drinking, and uses a 7 point (1-7) Likert scale for each of 8 items (questions). Scores range from 8 (less urge to drink) to 56 (more urge to drink).
Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Change From Baseline in Penn Alcohol Craving Scale (PACS)
PACS is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, ability to resist drinking and craving. Each item ranges from 0-6 with 6 indicating worse symptoms.
Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Change From Baseline in Beck Depression Inventory II (BDI-II) Total Score
BDI-II is a 21-item, participant-completed questionnaire to assess characteristics of depression. There is a 4-point scale for each item ranging from 0 (no depression) to 3 (very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression.
Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Change From Baseline Beck Anxiety Index (BAI) Total Score
BAI is a 21-item participant-completed questionnaire designed to assess the characteristics of anxiety. Each item is rated on a 4-point scale (0= not present; 3= present in the extreme). Total scores range from 0 to 63. Higher total scores indicate greater severity of anxiety symptoms.
Time frame: Baseline, Weeks 6 and 12
Change From Baseline in Plasma Gamma-Glutamyl Transferase (GGT)
Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Change From Baseline in Plasma Carbohydrate Deficient Transferrin (CDT)
Carbohydrate Deficient Transferrin is a laboratory test that measures alcohol consumption. Greater levels suggest recent alcohol consumption.
Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
12 -Item Short-Form Health Survey (SF-12) Scores: Physical Component Summary (PCS)
Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The PCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.
Time frame: Baseline and Week 12
12-Item Short-Form Health Survey (SF-12) Scores: Mental Component Summary (MCS)
Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The MCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.
Time frame: Baseline and Week 12
| Milestone | LY686017 | Placebo |
|---|---|---|
| Started | 94 | 96 |
| Full analysis set (fas) | 92 | 91 |
| Completed | 60 | 60 |
| Not completed | 34 | 36 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Protocol violation | 4 | 8 |
| Withdrew: Lost to follow-up | 10 | 13 |
| Withdrew: Withdrawal by subject | 15 | 9 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Acute alcohol withdrawal | 0 | 1 |
The Alcohol Timeline Followback (TLFB) is used in calculating the percent reduction in heavy drinking days. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day during last 4 weeks. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men.
| percent of heavy drinking days | LY686017 | Placebo |
|---|---|---|
| Week 4 | -45.63 ± 36.58 | -39.72 ± 36.52 |
| Week 8 | -60.98 ± 39.25 | -49.88 ± 48.43 |
| Week 12 | -68.56 ± 40.01 | -57.44 ± 42.02 |
| Week 16 | -69.46 ± 35.84 | -59.12 ± 40.42 |
The Alcohol Timeline Followback (TLFB) is used in calculating the percentage of days abstinent (days where no alcoholic drinks were consumed). The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Percentage days per month= (number of days where no alcoholic beverages were consumed/number of days in a month)\*100.
| percentage days abstinent per month | LY686017 | Placebo |
|---|---|---|
| Baseline | 11.63 ± 12.55 | 14.54 ± 17.32 |
| Week 4 | 30.28 ± 28.13 | 29.44 ± 26.56 |
| Week 8 | 40.73 ± 32.97 | 40.07 ± 33.68 |
| Week 12 | 51.43 ± 32.59 | 45.81 ± 34.74 |
| Week 16 | 52.92 ± 32.07 | 44.63 ± 36.84 |
The Alcohol Timeline Followback (TLFB) is used in calculating the number of drinks per drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv).
| drinks/drinking day/month | LY686017 | Placebo |
|---|---|---|
| Baseline | 7.04 ± 3.07 | 7.35 ± 3.78 |
| Week 4 | 3.92 ± 2.37 | 4.69 ± 3.64 |
| Week 8 | 3.03 ± 2.52 | 3.36 ± 3.31 |
| Week 12 | 2.32 ± 2.25 | 2.99 ± 3.70 |
| Week 16 | 2.31 ± 2.83 | 2.92 ± 3.38 |
The Alcohol Timeline Followback (TLFB) is used to assess the time to first heavy drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. Those who did not drink are considered to be "censored."
| days | LY686017 | Placebo |
|---|---|---|
| Time to First Heavy Drinking Day | 7.3 ± 16.8 | 8.0 ± 22.2 |
DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. All items for the DrInC are scored from 0-3 with higher scores indicating worse adverse consequences. Interpersonal subscale (10 items: scores range from 0-30) measures the impact of drinking on the participants' relationships. Physical subscale (8 items: scores range from 0-24) measures adverse physical states resulting from excessive drinking. Social subscale (7 items: scores range from 0-21) measures role fulfillment. Impulsive subscale (12 items: scores range from 0-36) measures sequelae of over drinking. Intrapersonal subscale (8 items: scores range from 0-24) measures subjective perceptions that may not be readily observable by others. Total scores range from 0-150, with higher scores indicating greater severity of symptoms.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| Interpersonal | -2.9 ± 5.5 | -3.9 ± 6.8 |
| Physical | -3.1 ± 4.0 | -2.3 ± 4.3 |
| Social | -2.0 ± 3.4 | -2.1 ± 4.1 |
| Impulsive | -2.5 ± 4.4 | -2.5 ± 5.8 |
| Intrapersonal | -4.2 ± 6.7 | -3.7 ± 6.2 |
| Total | -16.2 ± 22.2 | -16.4 ± 25.5 |
AUQ measures participant's feeling and thoughts about drinking, and uses a 7 point (1-7) Likert scale for each of 8 items (questions). Scores range from 8 (less urge to drink) to 56 (more urge to drink).
| units on a scale | LY686017 | Placebo |
|---|---|---|
| Week 1 | -2.9 ± 10.2 | -2.9 ± 8.8 |
| Week 2 | -5.0 ± 11.5 | -3.6 ± 11.1 |
| Week 3 | -5.3 ± 10.5 | -6.0 ± 9.6 |
| Week 4 | -5.9 ± 10.9 | -5.9 ± 10.1 |
| Week 6 | -6.4 ± 11.0 | -8.5 ± 11.7 |
| Week 8 | -5.8 ± 10.6 | -7.7 ± 11.8 |
| Week 10 | -5.7 ± 11.0 | -7.7 ± 12.7 |
| Week 12 | -6.3 ± 10.6 | -9.0 ± 12.5 |
PACS is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, ability to resist drinking and craving. Each item ranges from 0-6 with 6 indicating worse symptoms.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| Frequency: Week 1 | -1.0 ± 1.4 | -0.6 ± 1.3 |
| Frequency: Week 2 | -1.3 ± 1.4 | -1.0 ± 1.3 |
| Frequency: Week 3 | -1.4 ± 1.5 | -1.0 ± 1.3 |
| Frequency: Week 4 | -1.5 ± 1.6 | -1.3 ± 1.3 |
| Frequency: Week 6 | -1.5 ± 1.6 | -1.3 ± 1.3 |
| Frequency: Week 8 | -1.5 ± 1.5 | -1.3 ± 1.4 |
| Frequency: Week 10 | -1.7 ± 1.6 | -1.3 ± 1.3 |
| Frequency: Week 12 | -1.7 ± 1.5 | -1.4 ± 1.4 |
| Intensity: Week 1 | -1.2 ± 1.7 | -0.7 ± 1.4 |
| Intensity: Week 2 | -1.6 ± 1.6 | -1.0 ± 1.3 |
| Intensity: Week 3 | -1.7 ± 1.7 | -1.3 ± 1.4 |
| Intensity: Week 4 | -1.8 ± 1.8 | -1.4 ± 1.6 |
| Intensity: Week 6 | -2.0 ± 2.0 | -1.6 ± 1.7 |
| Intensity: Week 8 | -2.0 ± 1.8 | -1.5 ± 1.7 |
| Intensity: Week 10 | -2.1 ± 1.8 | -1.6 ± 1.6 |
| Intensity: Week 12 | -2.2 ± 1.6 | -1.8 ± 1.7 |
| Duration: Week 1 | -0.9 ± 1.6 | -0.4 ± 1.6 |
| Duration: Week 2 | -1.1 ± 1.7 | -0.6 ± 1.7 |
| Duration: Week 3 | -1.2 ± 1.8 | -0.7 ± 1.5 |
| Duration: Week 4 | -1.1 ± 1.7 | -0.8 ± 1.5 |
| Duration: Week 6 | -1.3 ± 1.9 | -0.9 ± 1.6 |
| Duration: Week 8 | -1.2 ± 1.6 | -1.0 ± 1.8 |
| Duration: Week 10 | -1.2 ± 1.8 | -1.0 ± 1.6 |
| Duration: Week 12 | -1.4 ± 1.8 | -1.0 ± 1.8 |
| Resistance: Week 1 | -1.2 ± 1.6 | -0.9 ± 1.7 |
| Resistance: Week 2 | -1.4 ± 1.7 | -1.0 ± 1.8 |
| Resistance: Week 3 | -1.4 ± 1.8 | -1.2 ± 1.6 |
| Resistance: Week 4 | -1.6 ± 1.9 | -1.3 ± 1.7 |
| Resistance: Week 6 | -1.6 ± 2.0 | -1.5 ± 2.0 |
| Resistance: Week 8 | -1.8 ± 1.9 | -1.5 ± 1.9 |
| Resistance: Week 10 | -1.7 ± 1.9 | -1.5 ± 1.8 |
| Resistance: Week 12 | -1.9 ± 1.8 | -1.4 ± 1.8 |
| Craving: Week 1 | -1.0 ± 1.2 | -0.6 ± 1.2 |
| Craving: Week 2 | -1.2 ± 1.3 | -0.9 ± 1.2 |
| Craving: Week 3 | -1.4 ± 1.3 | -1.1 ± 1.2 |
| Craving: Week 4 | -1.5 ± 1.4 | -1.2 ± 1.2 |
| Craving: Week 6 | -1.7 ± 1.4 | -1.4 ± 1.3 |
| Craving: Week 8 | -1.7 ± 1.4 | -1.4 ± 1.3 |
| Craving: Week 10 | -1.6 ± 1.4 | -1.4 ± 1.2 |
| Craving: Week 12 | -1.8 ± 1.4 | -1.5 ± 1.3 |
BDI-II is a 21-item, participant-completed questionnaire to assess characteristics of depression. There is a 4-point scale for each item ranging from 0 (no depression) to 3 (very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| Week 1 | 0.0 ± 4.1 | -1.4 ± 3.6 |
| Week 2 | -0.9 ± 4.1 | -1.0 ± 3.9 |
| Week 3 | -1.5 ± 4.7 | -1.2 ± 3.9 |
| Week 4 | -1.7 ± 5.7 | -2.0 ± 4.5 |
| Week 6 | -0.8 ± 5.8 | -1.7 ± 5.5 |
| Week 8 | -1.4 ± 5.3 | -3.2 ± 5.9 |
| Week 10 | -1.5 ± 6.3 | -2.8 ± 6.7 |
| Week 12 | -2.0 ± 5.9 | -3.0 ± 6.7 |
BAI is a 21-item participant-completed questionnaire designed to assess the characteristics of anxiety. Each item is rated on a 4-point scale (0= not present; 3= present in the extreme). Total scores range from 0 to 63. Higher total scores indicate greater severity of anxiety symptoms.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| Week 6 | -1.9 ± 6.6 | -2.3 ± 7.2 |
| Week 12 | -1.3 ± 6.7 | -2.0 ± 6.8 |
| units per liter (U/L) | LY686017 | Placebo |
|---|---|---|
| Week 1 | -5.4 ± 18.8 | -1.3 ± 9.4 |
| Week 2 | -6.6 ± 20.2 | -2.1 ± 12.9 |
| Week 3 | -9.7 ± 26.1 | -3.7 ± 13.7 |
| Week 4 | -8.0 ± 27.3 | -3.0 ± 14.2 |
| Week 6 | -10.9 ± 33.4 | -4.1 ± 17.8 |
| Week 8 | -10.9 ± 36.2 | -3.4 ± 20.6 |
| Week 10 | -12.2 ± 35.8 | -4.0 ± 26.4 |
| Week 12 | -11.5 ± 42.6 | -2.1 ± 20.1 |
Carbohydrate Deficient Transferrin is a laboratory test that measures alcohol consumption. Greater levels suggest recent alcohol consumption.
| percent CDT | LY686017 | Placebo |
|---|---|---|
| Week 1 | -0.1 ± 0.5 | -0.0 ± 0.7 |
| Week 2 | -0.2 ± 0.7 | -0.1 ± 0.8 |
| Week 3 | -0.1 ± 0.9 | -0.0 ± 1.2 |
| Week 4 | -0.2 ± 0.9 | 0.1 ± 1.5 |
| Week 6 | -0.1 ± 1.2 | 0.2 ± 1.5 |
| Week 8 | -0.0 ± 1.4 | 0.1 ± 1.3 |
| Week 10 | -0.1 ± 1.5 | 0.1 ± 0.8 |
| Week 12 | -0.0 ± 1.2 | 0.1 ± 0.7 |
Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The PCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| PCS: Baseline | 49.2 ± 8.7 | 50.2 ± 8.3 |
| PCS: Week 12 | 53.0 ± 8.6 | 51.4 ± 7.5 |
Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The MCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.
| units on a scale | LY686017 | Placebo |
|---|---|---|
| MCS: Baseline | 45.7 ± 11.6 | 44.2 ± 11.2 |
| MCS: Week 12 | 48.5 ± 10.0 | 49.7 ± 9.6 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY686017 | — | 0/92 (0%) | 73/92 (79.3%) |
| Placebo | — | 0/91 (0%) | 68/91 (74.7%) |
| Event | LY686017 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 7/92 | 14/91 |
| Upper respiratory tract infectionInfections and infestations | 10/92 | 14/91 |
| HeadacheNervous system disorders | 6/92 | 9/91 |
| Dry mouthGastrointestinal disorders | 9/92 | 6/91 |
| FatigueGeneral disorders | 8/92 | 7/91 |
| DizzinessNervous system disorders | 7/92 | 3/91 |
| SomnolenceNervous system disorders | 7/92 | 0/91 |
| DiarrhoeaGastrointestinal disorders | 5/92 | 3/91 |
| Back painMusculoskeletal and connective tissue disorders | 5/92 | 4/91 |
| InsomniaPsychiatric disorders | 5/92 | 3/91 |
Full Analysis Set: all randomized participants who received ≥1 dose study drug and contributed to post-baseline data.
| Age, Continuous(years) | LY686017 | Placebo | Total |
|---|---|---|---|
| Mean | 44.3 ± 10.5 | 43.0 ± 11.1 | 43.7 ± 10.8 |
| Sex: Female, Male(Participants) | LY686017 | Placebo | Total |
|---|---|---|---|
| Female | 33 | 36 | 69 |
| Male | 59 | 55 | 114 |
| Ethnicity (NIH/OMB)(Participants) | LY686017 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 86 | 87 | 173 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY686017 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 18 | 21 | 39 |
| White | 69 | 67 | 136 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Region of Enrollment(Participants) | LY686017 | Placebo | Total |
|---|---|---|---|
| United States | 92 | 91 | 183 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Dec 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 8 years 7 months after primary completion. A results delay was requested in May 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant